Status and phase
Conditions
Treatments
About
Phase II study of second line capecitabine plus oxaliplatin (XELOX) in patients with advanced biliary tract carcinoma after failure of gemcitabine-based chemotherapy.
Full description
XELOX
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
67 participants in 1 patient group
Loading...
Central trial contact
hoyeong lim, MD,Ph; sungju park
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal